ClinicalTrials.gg
CompletedNCT03394924Updated May 18, 2021Results posted

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis

A Phase 2 interventional study of EDP-305 1 mg and EDP-305 2.5 mg in Primary Biliary Cholangitis, sponsored by Enanta Pharmaceuticals, Inc. Completed at 86 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-05-18.

Sponsored by Enanta Pharmaceuticals, Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 83 studies in Liver Cirrhosis, Biliary with a site in United States — 11 open to participants now, 17 under way, 7 of them phase 3. Liver Cirrhosis, Biliary · United States.

Enrollment
25th of 65
68 · median 46
Started
2017
with 7 others
Phase 2
34 of 83
2 open now
Registered
42nd of 83
by date

Among the 83 studies in Liver Cirrhosis, Biliary with a site in United States, this one is the 25th largest by enrollment of the 65 interventional ones that give a count, is one of 8 that started in 2017, is one of 34 in phase 2, and was the 42nd registered.

Liver Cirrhosis, Biliary

214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.

Browse Liver Cirrhosis, Biliary studies →

Open to participants now

11 of the 83 studies in Liver Cirrhosis, Biliary with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Liver Cirrhosis, Biliary with a site in United States, or all of them as a file.
02

Study summary

A randomized, double-blind study to assess the safety, tolerability, PK and efficacy of EDP-305 in subjects with primary biliary cholangitis

03

Conditions studied

  • Primary Biliary Cholangitis

Keywords

  • PBC
  • Primary Biliary Cholangitis (PBC)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • An document signed and dated by the subject.
  • Male and female subjects of any ethnic origin between the ages of 18 and 75 years, inclusive
  • Male or female with a diagnosis of PBC by at least two of the following criteria:

    • History of ALP above for at least six months
    • Positive Anti-Mitochondrial Antibodies (AMA) titers (>1/40 on immunofluorescence or M2 positive by enzyme linked immunosorbent assay (ELISA) or positive PBC-specific antinuclear antibodies)
  • For subjects with no documented liver performed within 2 years, subjects must undergo a transient elastography (Fibroscan) showing liver stiffness \< 14.0 kPA
  • Must be on a stable dose of UDCA12-20 mg/kg/day for at least 6 months prior to Screening or intolerant of UDCA in the opinion of the Investigator (no UDCA for at least 12 weeks prior to Screening)
  • Alkaline Phosphatase (ALP) ≥ 1.67 × ULN and/or total >ULN but \< 2×ULN (\<2.4 mg/dL)
  • Subjects must have Screening laboratory values for surface antigen (HBsAg), anti- antibodies and HCV RNA negative and (HIV) 1 and 2 antibodies (Ab) as seronegative. Note: subjects previously infected by chronic hepatitis C and treated with direct acting antivirals (DAAs) with sustained virologic response (SVR) for at least 3 years will be allowed.
  • Female subjects of must agree to use two effective methods of from the date of Screening until 90 days after the last dose of EDP-305.
  • All male participants who have not had a vasectomy must use effective contraception from Day -1 to 90 days after their last dose of study drug.
  • Male subjects must agree to refrain from sperm donation from the date of Screening until 90 days after their last dose of study drug
  • Screening (BMI) of ≥18 kg/m2
  • Subject must be willing and able to adhere to the assessments, visit schedule, prohibitions and restrictions, as described in this protocol

Exclusion criteria

Exclusion Criteria:

  • Laboratory Screening Results:

    • >5 x
    • ALT >5 x ULN
    • Patients with Gilbert's syndrome will not be allowed due to interpretability of levels
    • Total white blood cells (WBC) \<3000 cells/mm3
    • (ANC) \<1500 cells/mm3
    • count \<140,000/mm3
    • (international normalized ratio, INR) >1.2
    • Serum creatinine >2 mg/dL or \<60 mL/min (based on Cockroft-Gault Method)
  • Suspected to have relevant nonalcoholic fatty liver disease (NAFLD) as based on the judgment of the Investigator at Screening
  • Use of known to have an effect on the liver of patients with PBC (eg, colchicine, methotrexate, azathioprine, or systemic ) in the three months preceding screening
  • Current use of fibrates, including fenofibrates. Note: Subjects who discontinued fibrates for at least 3 months before Screening can participate
  • Use of an experimental treatment for PBC within the past 6 months
  • Co-existing liver or biliary diseases, such as primary sclerosing cholangitis, choledocholithiasis, acute or chronic hepatitis, hepatitis, alcoholic liver disease, nonalcoholic steatohepatitis (NASH), acute infection of bile duct system or gall bladder, history of gastrointestinal bleeding (secondary to portal hypertension), cirrhosis, cholangiocarcinoma diagnosed or suspected liver cancers
  • Cirrhosis with or without complications, including history or presence of: spontaneous bacterial peritonitis, hepatocellular carcinoma
  • Hepatorenal syndrome (type I or II) or Screening serum creatinine > 2 mg/dL (178 μmol/L)
  • Prior variceal hemorrhage, uncontrolled encephalopathy, Class A, B and C, esophageal varices, or ascites within the previous 6 months of Screening (defined as date signed)
  • Medical conditions that may cause nonhepatic increases in ALP (e.g., Paget's disease)
  • Use of a new statin regimen from Screening and throughout study duration. NOTE: Subjects on a stable dose of statins for at least 3 months prior to Screening are allowed. No dose modification during the study will be allowed.
  • Use of immunosuppressants (eg, systemic corticosteroids) for more than 2 consecutive weeks in duration within 1 year prior to Screening.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    EDP-305 1 mg

    Subjects will take 2 tablets once a day orally for 12 weeks

    Drug: EDP-305 1 mg

  • Experimental
    EDP-305 2.5 mg

    Subjects will take 2 tablets once a day orally for 12 weeks

    Drug: EDP-305 2.5 mg

  • Placebo comparator
    Placebo

    Subjects will take two tablets once a day orally for 12 weeks

    Drug: Placebo

Interventions

  • Two tablets daily for 12 weeks

  • Two tablets daily for 12 weeks

  • DrugPlacebo

    Two tablets daily for 12 weeks

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With At Least a 20% Reduction in Alkaline Phosphatase (ALP) or Normalization of ALP at Week 12 Compared to Baseline

    Percent change was calculated as \[(ALP at Week 12 - ALP at Baseline)/ALP at Baseline\] \*100. The participant was considered to have successfully achieved a 20% reduction in ALP if the result was ≤-20. The participant was considered to have successfully achieved ALP normalization if ALP was abnormal at Baseline and normal at Week 12.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Percentage of Participants With a Treatment-Emergent Adverse Event (TEAE) During On-Treatment Period

    An adverse event (AE) was defined as any event, side effect, or untoward medical occurrence in a subject enrolled in a clinical trial whether or not it is considered to have a causal relationship to the study drug. A TEAE was an AE that first occurred or began previous to and worsened on or after the first dose date and before the last dose date +7 days.

    Time frame: Up to approximately Week 12

  2. Percentage of Participants With a Treatment-Emergent Serious Adverse Event (SAE) During On-Treatment Period

    A SAE is any untoward medical occurrence at any dose that results in death, is a life-threatening event, requires inpatient hospitalization or prolonged hospitalization of an existing hospitalization, results in permanent or prolonged disability or incapacity, is a congenital anomaly or birth defect in the offspring of a study subjects, or is a medically important event.

    Time frame: Up to approximately Week 12

  3. Percentage of Participants Who Stopped Study Treatment Due to a Treatment-Emergent Adverse Event (TEAE) During On-Treatment Period

    An adverse event (AE) was defined as any event, side effect, or untoward medical occurrence in a subject enrolled in a clinical trial whether or not it is considered to have a causal relationship to the study drug. A TEAE was an AE that first occurred or began previous to and worsened on or after the first dose date and before the last dose date +7 days.

    Time frame: Up to approximately Week 12

  4. Change From Baseline to Week 12 in Total, Conjugated and Unconjugated Bilirubin

    The data presented below was measured using least square mean change from baseline.

    Time frame: Baseline and Week 12

  5. Change From Baseline to Week 12 in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT)

    Time frame: Baseline and Week 12

  6. Change From Baseline to Week 12 in Noninvasive Liver Fibrosis Markers: Enhanced Liver Fibrosis (ELF) Panel and N-terminal Type III Collagen Propeptide (PRO C3)

    The ELF panel included hyaluronic acid (HA), procollagen III amino terminal peptide (PIIINP), and tissue inhibitor of metalloproteinase 1 (TIMP 1). This endpoint also presents PRO C3 results.

    Time frame: Baseline and Week 12

  7. Change From Baseline to Week 12 in Noninvasive Liver Fibrosis Markers: AST to Platelet Ratio Index (APRI) Score

    APRI was calculated as (\[AST level/AST upper limit of normal\]/\[Platelet count 1\^09/L\])×100. AST is aspartate aminotransferase. The aspartate transaminase to platelet ratio index (APRI) is used to assess liver fibrosis in participants with chronic liver disease. Scores range from 0 to ≥ 2.0, with scores \< 0.5 predictive of no liver fibrosis; scores \>1.5 significant fibrosis; and scores \> 2.0 indicative of cirrhosis. A negative change from baseline indicates a decrease in fibrosis.

    Time frame: Baseline and Week 12

  8. Change From Baseline to Week 12 in Noninvasive Liver Fibrosis Markers: Fibrosis-4 (FIB-4) Score

    Fibrosis-4 is the ratio of age in years and aminotransferase to platelet count. It is a non-invasive hepatic fibrosis index score that is calculated using formula: FIB-4 = (Age \[years\] x AST \[U/L\]) / (platelets \[10\^9/L\] x (square root of ALT \[U/L\])). A FIB-4 index of \< 1.45 indicates no or moderate fibrosis and an index of \> 3.25 indicates extensive fibrosis/cirrhosis. A positive change from Baseline indicates increased fibrosis.

    Time frame: Baseline and Week 12

  9. Change From Baseline to Week 12 in Fibrinogen and C Reactive Protein (CRP) Levels

    Time frame: Baseline and Week 12

  10. Change From Baseline to Week 12 in Interleukin (IL) and Tumor Necrosis Factor (TNF) Levels

    For IL, both IL6 and IL1β variants were analysed. For TNF, both TNF α and TNF β (also known as lymphotoxin alpha) variants were analyzed.

    Time frame: Baseline and Week 12

  11. Change From Baseline to Week 12 in Haptoglobin and Alpha2 Macroglobulin Levels

    Time frame: Baseline and Week 12

  12. Change From Baseline to Week 12 in Triglycerides (TG), Total Cholesterol (TC), High Density Lipoprotein Cholesterol (HDL-C), Low Density Lipoprotein Cholesterol (LDL-C)

    Time frame: Baseline and Week 12

  13. Change From Baseline to Week 12 in Domain and Total Scores on the 5D-Itch Scale

    The 5D-Itch scale is a multidimensional questionnaire completed by participants to quantify the magnitude of pruritus, assessed considering the past 2 weeks. Scale range is 1 to 5 covering five dimensions: duration (1=Less than 6 hrs/day to 5=All day), degree (1=Not present to 5=Unbearable), direction (1=Completely resolved to 5=Getting worse), disability (for Sleep rated as 1=Never affects sleep to 5=Delays falling asleep and frequently wakes me up at night; for Leisure/Social, Housework/Errands and Work/School rated as 1=Never affects activity to 5=Always affects activity), and distribution (assess if itching is present in 16 body locations, scored as 1=present at 0-2 locations to 5=present at 14-16 locations). Total scores (including highest disability score obtained from any of the daily activities) ranged between 5 and 25 where higher scores indicated more severe itching. Negative change scores indicate improvement from the baseline score.

    Time frame: Baseline and Week 12

  14. Change From Baseline to Week 12 in Visual Analog Score (VAS) for Itching

    An itch VAS (0-100mm) was used to record the intensity of the event. Participants drew a line on a scale corresponding to the maximum intensity of itch. Lines drawn towards the right of the line indicated greater itching and higher scores indicated more severe itching. Negative change from baseline indicates decrease in itching.

    Time frame: Baseline to Week 12

  15. Change From Baseline to Week 12 in Domain Scores on the Primary Biliary Cholangitis-40 (PBC-40) Quality of Life (QoL) Assessment

    The PBC-40 is a survey measuring health related quality of life in participants with PBC. The 40 questions from the PBC-40 questionnaire are scored from 1-5, with 5 representing the highest impact and 1 the lowest impact of PBC on the quality of life. Six domains were computed from the 40 questions: symptoms (score range 7-35), itch (0-15), fatigue (11-55), cognition (6-30), social (8-50) and emotional (1-15). Higher scores indicate worse quality of life and negative change scores indicate improvement from the baseline score.

    Time frame: Baseline and Week 12

  16. Maximum Plasma Concentration (Cmax) of EDP-305 and Its Metabolites

    Metabolites of EDP-305 are EP-022571, EP-022572, and EP-022679.

    Time frame: Day 1 and Week 12: Pre-dose and 2, 6 and 8 hours post-dose

  17. Time to Maximum Plasma Concentration (Tmax) of EDP-305 and Its Metabolites

    Metabolites of EDP-305 are EP-022571, EP-022572, and EP-022679.

    Time frame: Day 1 and Week 12: Pre-dose and 2, 6 and 8 hours post-dose

  18. Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of EDP-305 and Its Metabolites

    Metabolites of EDP-305 are EP-022571, EP-022572, and EP-022679.

    Time frame: Day 1 and Week 12: Pre-dose and 2, 6 and 8 hours post-dose

  19. Percentage Change From Baseline to Week 12 in Fibroblast Growth Factor 19 (FGF19), 7α-OH-4-cholesten-3-one (C4) and Bile Acid (BA) Concentrations

    FGF19 was measured in plasma. BA was measured in serum. C4 was measured in serum.

    Time frame: Baseline and Week 12

  20. Percentage Change From Baseline to Week 12 in AUC0-8 and AUC2-8 of Fibroblast Growth Factor 19 (FGF19), 7α-OH-4-cholesten-3-one (C4) and Bile Acid (BA)

    AUC0-8 is area under the biomarker concentration-time curve from time zero to 8 hours. AUC2-8 is area under the biomarker concentration-time curve from 2 hours to 8 hours. FGF19 was measured in plasma. BA was measured in serum. C4 was measured in serum.

    Time frame: Day 1 and Week 12: Pre-dose and 2, 6 and 8 hours post-dose

07

Results

Posted May 18, 2021

Participant flow

The trial included 68 participants from 43 sites in Australia, Canada, Europe and the United States from December 2017 to January 2020.

Participant flow — Overall Study
MilestoneEDP-305 1 mgEDP-305 2.5 mgPlacebo
Started31289
Completed28229
Not completed360
Withdrew: Adverse event050
Withdrew: Withdrawal by subject200
Withdrew: Lost to follow-up010
Withdrew: Did not meet all inclusion criteria100

Outcome measures

PrimaryPercentage of Participants With At Least a 20% Reduction in Alkaline Phosphatase (ALP) or Normalization of ALP at Week 12 Compared to Baseline

Percent change was calculated as \[(ALP at Week 12 - ALP at Baseline)/ALP at Baseline\] \*100. The participant was considered to have successfully achieved a 20% reduction in ALP if the result was ≤-20. The participant was considered to have successfully achieved ALP normalization if ALP was abnormal at Baseline and normal at Week 12.

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With At Least a 20% Reduction in Alkaline Phosphatase (ALP) or Normalization of ALP at Week 12 Compared to Baseline
percentage of participantsEDP-305 1 mgEDP-305 2.5 mgPlacebo
Percentage of Participants With At Least a 20% Reduction in Alkaline Phosphatase (ALP) or Normalization of ALP at Week 12 Compared to Baseline45.246.411.1
Statistical analysis
  • EDP-305 1 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.106 · Odds ratio (or): 5.6 · 95% CI 0.6 to 52
  • EDP-305 2.5 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.063 · Odds ratio (or): 7 · 95% CI 0.75 to 65.22
SecondaryPercentage of Participants With a Treatment-Emergent Adverse Event (TEAE) During On-Treatment Period

An adverse event (AE) was defined as any event, side effect, or untoward medical occurrence in a subject enrolled in a clinical trial whether or not it is considered to have a causal relationship to the study drug. A TEAE was an AE that first occurred or began previous to and worsened on or after the first dose date and before the last dose date +7 days.

Time frame:
Up to approximately Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants With a Treatment-Emergent Adverse Event (TEAE) During On-Treatment Period
Percentage of participantsEDP-305 1 mgEDP-305 2.5 mgPlacebo
Percentage of Participants With a Treatment-Emergent Adverse Event (TEAE) During On-Treatment Period71.089.388.9
SecondaryPercentage of Participants With a Treatment-Emergent Serious Adverse Event (SAE) During On-Treatment Period

A SAE is any untoward medical occurrence at any dose that results in death, is a life-threatening event, requires inpatient hospitalization or prolonged hospitalization of an existing hospitalization, results in permanent or prolonged disability or incapacity, is a congenital anomaly or birth defect in the offspring of a study subjects, or is a medically important event.

Time frame:
Up to approximately Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants With a Treatment-Emergent Serious Adverse Event (SAE) During On-Treatment Period
Percentage of participantsEDP-305 1 mgEDP-305 2.5 mgPlacebo
Percentage of Participants With a Treatment-Emergent Serious Adverse Event (SAE) During On-Treatment Period3.27.10
SecondaryPercentage of Participants Who Stopped Study Treatment Due to a Treatment-Emergent Adverse Event (TEAE) During On-Treatment Period

An adverse event (AE) was defined as any event, side effect, or untoward medical occurrence in a subject enrolled in a clinical trial whether or not it is considered to have a causal relationship to the study drug. A TEAE was an AE that first occurred or began previous to and worsened on or after the first dose date and before the last dose date +7 days.

Time frame:
Up to approximately Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Who Stopped Study Treatment Due to a Treatment-Emergent Adverse Event (TEAE) During On-Treatment Period
Percentage of participantsEDP-305 1 mgEDP-305 2.5 mgPlacebo
Percentage of Participants Who Stopped Study Treatment Due to a Treatment-Emergent Adverse Event (TEAE) During On-Treatment Period3.217.90
SecondaryChange From Baseline to Week 12 in Total, Conjugated and Unconjugated Bilirubin

The data presented below was measured using least square mean change from baseline.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · μmol/L
Change From Baseline to Week 12 in Total, Conjugated and Unconjugated Bilirubin
μmol/LEDP-305 1 mgEDP-305 2.5 mgPlacebo
Total-0.04 (-0.93 to 0.86)-0.31 (-1.35 to 0.74)-0.50 (-2.13 to 1.12)
Conjugated-0.55 (-1.03 to -0.06)-0.51 (-1.08 to 0.06)0.13 (-0.75 to 1.00)
Unconjugated0.71 (-0.02 to 1.44)0.22 (-0.61 to 1.06)-0.50 (-1.81 to 0.81)
Statistical analysis
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.616 · Least squares mean difference: 0.47 · 95% CI -1.39 to 2.32
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.844 · Least squares mean difference: 0.19 · 95% CI -1.78 to 2.16
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.18 · Least squares mean difference: -0.67 · 95% CI -1.67 to 0.32
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.239 · Least squares mean difference: -0.64 · 95% CI -1.71 to 0.44
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.116 · Least squares mean difference: 1.21 · 95% CI -0.31 to 2.73
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.36 · Least squares mean difference: 0.72 · 95% CI -0.84 to 2.28
SecondaryChange From Baseline to Week 12 in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT)
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · U/L
Change From Baseline to Week 12 in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT)
U/LEDP-305 1 mgEDP-305 2.5 mgPlacebo
ALT-17.35 (-24.45 to -10.25)-13.14 (-21.58 to 4.71)8.20 (-4.61 to 21.02)
AST-12.08 (-17.49 to -6.68)-11.51 (-17.91 to -5.10)9.33 (-0.43 to 19.09)
GGT-95.91 (-114.12 to -77.70)-124.55 (-146.00 to -103.11)-9.42 (-42.19 to 23.35)
Statistical analysis
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.001 · Least squares mean difference: -25.55 · 95% CI -40.07 to -11.04
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.009 · Least squares mean difference: -21.35 · 95% CI -37.1 to -5.6
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.000 · Least squares mean difference: -21.42 · 95% CI -32.48 to -10.35
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.001 · Least squares mean difference: -20.84 · 95% CI -32.8 to -8.87
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.000 · Least squares mean difference: -86.49 · 95% CI -123.78 to -49.21
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.000 · Least squares mean difference: -115.13 · 95% CI -155.04 to -75.22
SecondaryChange From Baseline to Week 12 in Noninvasive Liver Fibrosis Markers: Enhanced Liver Fibrosis (ELF) Panel and N-terminal Type III Collagen Propeptide (PRO C3)

The ELF panel included hyaluronic acid (HA), procollagen III amino terminal peptide (PIIINP), and tissue inhibitor of metalloproteinase 1 (TIMP 1). This endpoint also presents PRO C3 results.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · μg/L
Change From Baseline to Week 12 in Noninvasive Liver Fibrosis Markers: Enhanced Liver Fibrosis (ELF) Panel and N-terminal Type III Collagen Propeptide (PRO C3)
μg/LEDP-305 1 mgEDP-305 2.5 mgPlacebo
HA1.17 (-16.69 to 19.03)-1.16 (-22.20 to 19.87)27.83 (-4.20 to 59.86)
PIIINP-0.08 (-1.28 to 1.11)-0.77 (-2.20 to 0.65)3.01 (0.72 to 5.30)
TIMP 1-16.29 (-32.31 to -0.27)-20.90 (-39.58 to -2.22)25.66 (-3.64 to 54.97)
PRO C3-0.67 (-4.97 to 3.63)2.33 (-2.31 to 6.96)9.06 (2.16 to 15.95)
Statistical analysis
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.148 · Least squares mean difference: -26.66 · 95% CI -63.1 to 9.79
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.142 · Least squares mean difference: -28.99 · 95% CI -68.02 to 10.05
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.02 · Least squares mean difference: -3.09 · 95% CI -5.68 to -0.51
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.009 · Least squares mean difference: -3.79 · 95% CI -6.6 to -0.97
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.015 · Least squares mean difference: -41.96 · 95% CI -75.47 to -8.44
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.011 · Least squares mean difference: -46.56 · 95% CI -81.91 to -11.21
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.018 · Least squares mean difference: -9.73 · 95% CI -17.7 to -1.75
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.125 · Least squares mean difference: -6.73 · 95% CI -15.41 to 1.95
SecondaryChange From Baseline to Week 12 in Noninvasive Liver Fibrosis Markers: AST to Platelet Ratio Index (APRI) Score

APRI was calculated as (\[AST level/AST upper limit of normal\]/\[Platelet count 1\^09/L\])×100. AST is aspartate aminotransferase. The aspartate transaminase to platelet ratio index (APRI) is used to assess liver fibrosis in participants with chronic liver disease. Scores range from 0 to ≥ 2.0, with scores \< 0.5 predictive of no liver fibrosis; scores \>1.5 significant fibrosis; and scores \> 2.0 indicative of cirrhosis. A negative change from baseline indicates a decrease in fibrosis.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Index
Change From Baseline to Week 12 in Noninvasive Liver Fibrosis Markers: AST to Platelet Ratio Index (APRI) Score
IndexEDP-305 1 mgEDP-305 2.5 mgPlacebo
Change From Baseline to Week 12 in Noninvasive Liver Fibrosis Markers: AST to Platelet Ratio Index (APRI) Score-0.16 (-0.25 to 0.06)-0.12 (-0.23 to 0.01)0.22 (0.05 to 0.38)
Statistical analysis
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.000 · Least squares mean difference: -0.37 · 95% CI -0.56 to -0.18
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.002 · Least squares mean difference: -0.33 · 95% CI -0.54 to -0.13
SecondaryChange From Baseline to Week 12 in Noninvasive Liver Fibrosis Markers: Fibrosis-4 (FIB-4) Score

Fibrosis-4 is the ratio of age in years and aminotransferase to platelet count. It is a non-invasive hepatic fibrosis index score that is calculated using formula: FIB-4 = (Age \[years\] x AST \[U/L\]) / (platelets \[10\^9/L\] x (square root of ALT \[U/L\])). A FIB-4 index of \< 1.45 indicates no or moderate fibrosis and an index of \> 3.25 indicates extensive fibrosis/cirrhosis. A positive change from Baseline indicates increased fibrosis.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Index
Change From Baseline to Week 12 in Noninvasive Liver Fibrosis Markers: Fibrosis-4 (FIB-4) Score
IndexEDP-305 1 mgEDP-305 2.5 mgPlacebo
Change From Baseline to Week 12 in Noninvasive Liver Fibrosis Markers: Fibrosis-4 (FIB-4) Score-0.14 (-0.29 to 0.01)-0.05 (-0.22 to 0.11)0.21 (-0.06 to 0.47)
Statistical analysis
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.026 · Least squares mean difference: -0.35 · 95% CI -0.65 to -0.04
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.104 · Least squares mean difference: -0.26 · 95% CI -0.57 to 0.05
SecondaryChange From Baseline to Week 12 in Fibrinogen and C Reactive Protein (CRP) Levels
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 12 in Fibrinogen and C Reactive Protein (CRP) Levels
mg/dLEDP-305 1 mgEDP-305 2.5 mgPlacebo
Fibrinogen16.28 (-5.39 to 37.95)41.25 (15.56 to 66.93)9.47 (-28.82 to 47.76)
CRP-0.57 (-1.62 to 0.49)-2.69 (-3.89 to -1.50)0.41 (-1.53 to 2.34)
Statistical analysis
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.757 · Least squares mean difference: 6.81 · 95% CI -37.17 to 50.78
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.174 · Least squares mean difference: 31.77 · 95% CI -14.42 to 77.97
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.378 · Least squares mean difference: -0.98 · 95% CI -3.18 to 1.23
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.008 · Least squares mean difference: -3.1 · 95% CI -5.38 to -0.83
SecondaryChange From Baseline to Week 12 in Interleukin (IL) and Tumor Necrosis Factor (TNF) Levels

For IL, both IL6 and IL1β variants were analysed. For TNF, both TNF α and TNF β (also known as lymphotoxin alpha) variants were analyzed.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · ng/L
Change From Baseline to Week 12 in Interleukin (IL) and Tumor Necrosis Factor (TNF) Levels
ng/LEDP-305 1 mgEDP-305 2.5 mgPlacebo
IL60.73 (-0.97 to 2.43)-2.10 (-4.03 to -0.17)0.39 (-2.57 to 3.34)
IL1βNA (NA to NA)NA (NA to NA)NA (NA to NA)
TNF α-0.15 (-0.38 to 0.09)-0.01 (-0.28 to 0.25)0.39 (-0.03 to 0.81)
TNF βNA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.841 · Least squares mean difference: 0.34 · 95% CI -3.07 to 3.76
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.163 · Least squares mean difference: -2.49 · 95% CI -6.01 to 1.04
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.03 · Least squares mean difference: -0.53 · 95% CI -1.02 to -0.05
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.11 · Least squares mean difference: -0.4 · 95% CI -0.9 to 0.09
SecondaryChange From Baseline to Week 12 in Haptoglobin and Alpha2 Macroglobulin Levels
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · g/L
Change From Baseline to Week 12 in Haptoglobin and Alpha2 Macroglobulin Levels
g/LEDP-305 1 mgEDP-305 2.5 mgPlacebo
Haptoglobin-0.14 (-0.27 to -0.01)-0.18 (-0.33 to -0.03)-0.15 (-0.38 to 0.08)
Alpha2 Macroglobulin-0.02 (-0.09 to 0.05)-0.00 (-0.08 to 0.08)0.02 (-0.11 to 0.15)
Statistical analysis
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.944 · Least squares mean difference: 0.01 · 95% CI -0.25 to 0.27
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.83 · Least squares mean difference: -0.03 · 95% CI -0.3 to 0.24
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.546 · Least squares mean difference: -0.04 · 95% CI -0.19 to 0.1
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.785 · Least squares mean difference: -0.02 · 95% CI -0.18 to 0.13
SecondaryChange From Baseline to Week 12 in Triglycerides (TG), Total Cholesterol (TC), High Density Lipoprotein Cholesterol (HDL-C), Low Density Lipoprotein Cholesterol (LDL-C)
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · mmol/L
Change From Baseline to Week 12 in Triglycerides (TG), Total Cholesterol (TC), High Density Lipoprotein Cholesterol (HDL-C), Low Density Lipoprotein Cholesterol (LDL-C)
mmol/LEDP-305 1 mgEDP-305 2.5 mgPlacebo
TG-0.13 (-0.25 to -0.00)0.01 (-0.13 to 0.16)0.05 (-0.17 to 0.27)
TC-0.47 (-0.80 to -0.14)-0.46 (-0.85 to -0.08)0.17 (-0.42 to 0.76)
HDL-C-0.16 (-0.31 to -0.02)-0.46 (-0.62 to -0.30)-0.24 (-0.49 to 0.01)
LDL-C-0.21 (-0.47 to 0.05)-0.01 (-0.31 to 0.29)0.29 (-0.19 to 0.76)
Statistical analysis
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.176 · Least squares mean difference: -0.17 · 95% CI -0.43 to 0.08
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.783 · Least squares mean difference: -0.04 · 95% CI -0.3 to 0.23
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.061 · Least squares mean difference: -0.64 · 95% CI -1.31 to 0.03
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.08 · Least squares mean difference: -0.63 · 95% CI -1.34 to 0.08
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.584 · Least squares mean difference: 0.08 · 95% CI -0.21 to 0.37
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.148 · Least squares mean difference: -0.22 · 95% CI -0.51 to 0.08
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.074 · Least squares mean difference: -0.5 · 95% CI -1.04 to 0.05
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.304 · Least squares mean difference: -0.3 · 95% CI -0.87 to 0.28
SecondaryChange From Baseline to Week 12 in Domain and Total Scores on the 5D-Itch Scale

The 5D-Itch scale is a multidimensional questionnaire completed by participants to quantify the magnitude of pruritus, assessed considering the past 2 weeks. Scale range is 1 to 5 covering five dimensions: duration (1=Less than 6 hrs/day to 5=All day), degree (1=Not present to 5=Unbearable), direction (1=Completely resolved to 5=Getting worse), disability (for Sleep rated as 1=Never affects sleep to 5=Delays falling asleep and frequently wakes me up at night; for Leisure/Social, Housework/Errands and Work/School rated as 1=Never affects activity to 5=Always affects activity), and distribution (assess if itching is present in 16 body locations, scored as 1=present at 0-2 locations to 5=present at 14-16 locations). Total scores (including highest disability score obtained from any of the daily activities) ranged between 5 and 25 where higher scores indicated more severe itching. Negative change scores indicate improvement from the baseline score.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Scores on a scale
Change From Baseline to Week 12 in Domain and Total Scores on the 5D-Itch Scale
Scores on a scaleEDP-305 1 mgEDP-305 2.5 mgPlacebo
Duration0.01 (-0.27 to 0.29)0.41 (0.11 to 0.71)-0.24 (-0.73 to 0.25)
Degree0.00 (-0.25 to 0.26)0.65 (0.37 to 0.93)-0.53 (-0.96 to 0.10)
Direction-0.63 (-1.12 to -0.15)0.36 (-0.17 to 0.90)-0.65 (-1.46 to 0.16)
Disability-0.24 (-0.63 to 0.15)0.85 (0.42 to 1.28)-0.61 (-1.28 to 0.05)
Distribution0.07 (-0.32 to 0.45)0.81 (0.38 to 1.24)-0.42 (-1.08 to 0.24)
Total-0.95 (-2.29 to 0.39)3.19 (1.74 to 4.64)-3.16 (-5.50 to -0.82)
Statistical analysis
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.378 · Least squares mean difference: 0.25 · 95% CI -0.32 to 0.82
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.03 · Least squares mean difference: 0.65 · 95% CI 0.07 to 1.23
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.036 · Least squares mean difference: 0.53 · 95% CI 0.04 to 1.03
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.000 · Least squares mean difference: 1.18 · 95% CI 0.67 to 1.69
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.971 · Least squares mean difference: 0.02 · 95% CI -0.92 to 0.96
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.042 · Least squares mean difference: 1.01 · 95% CI 0.04 to 1.99
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.336 · Least squares mean difference: 0.37 · 95% CI -0.4 to 1.14
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.000 · Least squares mean difference: 1.46 · 95% CI 0.67 to 2.26
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.214 · Least squares mean difference: 0.48 · 95% CI -0.29 to 1.25
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.003 · Least squares mean difference: 1.23 · 95% CI 0.44 to 2.02
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.103 · Least squares mean difference: 2.21 · 95% CI -0.47 to 4.9
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.000 · Least squares mean difference: 6.35 · 95% CI 3.57 to 9.13
SecondaryChange From Baseline to Week 12 in Visual Analog Score (VAS) for Itching

An itch VAS (0-100mm) was used to record the intensity of the event. Participants drew a line on a scale corresponding to the maximum intensity of itch. Lines drawn towards the right of the line indicated greater itching and higher scores indicated more severe itching. Negative change from baseline indicates decrease in itching.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · Scores on a scale
Change From Baseline to Week 12 in Visual Analog Score (VAS) for Itching
Scores on a scaleEDP-305 1 mgEDP-305 2.5 mgPlacebo
Change From Baseline to Week 12 in Visual Analog Score (VAS) for Itching0.55 (-8.35 to 9.44)13.64 (4.00 to 23.29)-11.93 (-27.05 to 3.18)
Statistical analysis
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.16 · Least squares mean difference: 12.48 · 95% CI -5.09 to 30.06
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.006 · Least squares mean difference: 25.58 · 95% CI 7.67 to 43.48
SecondaryChange From Baseline to Week 12 in Domain Scores on the Primary Biliary Cholangitis-40 (PBC-40) Quality of Life (QoL) Assessment

The PBC-40 is a survey measuring health related quality of life in participants with PBC. The 40 questions from the PBC-40 questionnaire are scored from 1-5, with 5 representing the highest impact and 1 the lowest impact of PBC on the quality of life. Six domains were computed from the 40 questions: symptoms (score range 7-35), itch (0-15), fatigue (11-55), cognition (6-30), social (8-50) and emotional (1-15). Higher scores indicate worse quality of life and negative change scores indicate improvement from the baseline score.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Scores on a scale
Change From Baseline to Week 12 in Domain Scores on the Primary Biliary Cholangitis-40 (PBC-40) Quality of Life (QoL) Assessment
Scores on a scaleEDP-305 1 mgEDP-305 2.5 mgPlacebo
Symptoms-0.21 (-1.47 to 1.06)-1.46 (-2.93 to 0.00)-0.06 (-2.30 to 2.18)
Itch0.18 (-0.72 to 1.09)1.74 (0.69 to 2.78)-1.73 (-3.33 to -0.13)
Fatigue-0.36 (-2.58 to 1.86)-0.22 (-2.79 to 2.34)0.10 (-3.82 to 4.01)
Cognition-0.21 (-1.46 to 1.04)0.82 (-0.63 to 2.27)-0.48 (-2.66 to 1.71)
Social-0.38 (-2.22 to 1.46)0.96 (-1.17 to 3.08)1.73 (-1.52 to 4.99)
Emotional-0.77 (-1.54 to 0.01)0.23 (-0.68 to 1.13)-0.15 (-1.52 to 1.22)
Statistical analysis
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.908 · Least squares mean difference: -0.15 · 95% CI -2.72 to 2.43
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.298 · Least squares mean difference: -1.41 · 95% CI -4.09 to 1.27
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.042 · Least squares mean difference: 1.91 · 95% CI 0.07 to 3.76
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.001 · Least squares mean difference: 3.47 · 95% CI 1.55 to 5.38
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.839 · Least squares mean difference: -0.46 · 95% CI -4.96 to 4.04
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.891 · Least squares mean difference: -0.32 · 95% CI -5.00 to 4.36
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.834 · Least squares mean difference: 0.26 · 95% CI -2.25 to 2.77
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.327 · Least squares mean difference: 1.3 · 95% CI -1.33 to 3.92
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.262 · Least squares mean difference: -2.12 · 95% CI -5.86 to 1.62
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.69 · Least squares mean difference: -0.78 · 95% CI -4.68 to 3.12
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.433 · Least squares mean difference: -0.62 · 95% CI -2.19 to 0.95
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.653 · Least squares mean difference: 0.37 · 95% CI -1.28 to 2.03
SecondaryMaximum Plasma Concentration (Cmax) of EDP-305 and Its Metabolites

Metabolites of EDP-305 are EP-022571, EP-022572, and EP-022679.

Time frame:
Day 1 and Week 12: Pre-dose and 2, 6 and 8 hours post-dose
Reported as:
Geometric mean · ng/mL
Maximum Plasma Concentration (Cmax) of EDP-305 and Its Metabolites
ng/mLEDP-305 1 mg - Pharmacokinetic SubstudyEDP-305 2.5 mg - Pharmacokinetic Substudy
EDP-305 Day 115.4 ± 44.3027.9 ± 54.19
EDP-305 Week 1210.8 ± 67.7750.4 ± 53.20
EP-022571 Day 10.5 ± 44.580.6 ± 61.81
EP-022571 Week 120.2 ± 59.571.3 ± 160.28
EP-022572 Day 10.5 ± 41.690.8 ± 38.27
EP-022572 Week 120.2 ± 41.741.6 ± 138.55
EP-022679 Day 10.8 ± 113.241.7 ± 115.17
EP-022679 Week 120.6 ± 147.8110.9 ± 352.53
SecondaryTime to Maximum Plasma Concentration (Tmax) of EDP-305 and Its Metabolites

Metabolites of EDP-305 are EP-022571, EP-022572, and EP-022679.

Time frame:
Day 1 and Week 12: Pre-dose and 2, 6 and 8 hours post-dose
Reported as:
Median · hours
Time to Maximum Plasma Concentration (Tmax) of EDP-305 and Its Metabolites
hoursEDP-305 1 mg - Pharmacokinetic SubstudyEDP-305 2.5 mg - Pharmacokinetic Substudy
EDP-305 Day 16.00 (2.02 to 6.03)6.02 (2.00 to 8.00)
EDP-305 Week 127.01 (6.00 to 8.02)6.01 (2.05 to 8.02)
EP-022571 Day 12.00 (2.00 to 6.00)6.00 (2.00 to 6.10)
EP-022571 Week 126.00 (2.00 to 6.00)4.00 (2.00 to 6.10)
EP-022572 Day 12.00 (2.00 to 8.00)6.00 (2.00 to 6.10)
EP-022572 Week 126.00 (6.00 to 8.00)4.00 (2.00 to 6.00)
EP-022679 Day 16.00 (6.00 to 8.00)6.10 (2.00 to 8.00)
EP-022679 Week 126.00 (6.00 to 8.00)6.00 (6.00 to 8.00)
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of EDP-305 and Its Metabolites

Metabolites of EDP-305 are EP-022571, EP-022572, and EP-022679.

Time frame:
Day 1 and Week 12: Pre-dose and 2, 6 and 8 hours post-dose
Reported as:
Geometric mean · h*ng/mL
Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of EDP-305 and Its Metabolites
h*ng/mLEDP-305 1 mg - Pharmacokinetic SubstudyEDP-305 2.5 mg - Pharmacokinetic Substudy
EDP-305 Day 185.50 ± 51.5795.30 ± 141.72
EDP-305 Week 1267.60 ± 75.47316.20 ± 42.34
EP-022571 Day 12.30 ± 37.322.00 ± 132.47
EP-022571 Week 120.90 ± 78.757.30 ± 154.62
EP-022572 Day 12.50 ± 32.372.90 ± 96.70
EP-022572 Week 121.20 ± 53.1210.10 ± 148.55
EP-022679 Day 13.70 ± 109.305.00 ± 305.62
EP-022679 Week 123.00 ± 203.0457.00 ± 343.47
SecondaryPercentage Change From Baseline to Week 12 in Fibroblast Growth Factor 19 (FGF19), 7α-OH-4-cholesten-3-one (C4) and Bile Acid (BA) Concentrations

FGF19 was measured in plasma. BA was measured in serum. C4 was measured in serum.

Time frame:
Baseline and Week 12
Reported as:
Mean · Percentage change from baseline
Percentage Change From Baseline to Week 12 in Fibroblast Growth Factor 19 (FGF19), 7α-OH-4-cholesten-3-one (C4) and Bile Acid (BA) Concentrations
Percentage change from baselineEDP-305 1 mgEDP-305 2.5 mgPlacebo
FGF1928.10 ± 94.52646.90 ± 76.66739.83 ± 100.579
C4-18.066 ± 114.9959-61.960 ± 42.860339.839 ± 163.6265
BA-21.79 ± 74.581-15.79 ± 112.9343.17 ± 48.656
Statistical analysis
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.971 · Least squares mean difference: 1.34 · 95% CI -71.51 to 74.18
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.882 · Least squares mean difference: 5.54 · 95% CI -68.86 to 79.95
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.242 · Least squares mean difference: -51.66 · 95% CI -139.27 to 35.96
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.042 · Least squares mean difference: -94.3 · 95% CI -184.85 to -3.75
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.52 · Least squares mean difference: -24.57 · 95% CI -101.03 to 51.89
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.672 · Least squares mean difference: -17.96 · 95% CI -103.07 to 67.16
SecondaryPercentage Change From Baseline to Week 12 in AUC0-8 and AUC2-8 of Fibroblast Growth Factor 19 (FGF19), 7α-OH-4-cholesten-3-one (C4) and Bile Acid (BA)

AUC0-8 is area under the biomarker concentration-time curve from time zero to 8 hours. AUC2-8 is area under the biomarker concentration-time curve from 2 hours to 8 hours. FGF19 was measured in plasma. BA was measured in serum. C4 was measured in serum.

Time frame:
Day 1 and Week 12: Pre-dose and 2, 6 and 8 hours post-dose
Reported as:
Mean · Percentage change from baseline
Percentage Change From Baseline to Week 12 in AUC0-8 and AUC2-8 of Fibroblast Growth Factor 19 (FGF19), 7α-OH-4-cholesten-3-one (C4) and Bile Acid (BA)
Percentage change from baselineEDP-305 1 mgEDP-305 2.5 mgPlacebo
FGF19 AUC0-824.9 ± 68.9025.0 ± 71.72-25.9 ± NA
FGF19 AUC 2-87.8 ± 86.2518.9 ± 66.35-25.3 ± NA
C4 AUC0-83.7 ± 51.74100.0 ± NA138.2 ± NA
C4 AUC2-8-9.2 ± 66.30-100.0 ± NA122.5 ± NA
BA AUC0-8-20.7 ± 74.80-51.5 ± 41.06-26.1 ± NA
BA AUC2-8-33.6 ± 76.26-42.8 ± 56.77-24.4 ± NA
Statistical analysis
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.611 · Least squares mean difference: 44.54 · 95% CI -205.97 to 295.06
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.819 · Least squares mean difference: -29.98 · 95% CI -411.28 to 351.31
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.818 · Least squares mean difference: 24.41 · 95% CI -251.92 to 300.74
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.948 · Least squares mean difference: -10.53 · 95% CI -435.33 to 414.27
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.412 · Least squares mean difference: -91.7 · 95% CI -475.92 to 292.51
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.094 · Least squares mean difference: -250.18 · 95% CI -605.33 to 104.98
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.266 · Least squares mean difference: -83.7 · 95% CI -279.15 to 111.75
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.047 · Least squares mean difference: -238.19 · 95% CI -470.22 to -6.15
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.694 · Least squares mean difference: 28.41 · 95% CI -180.2 to 237.02
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.615 · Least squares mean difference: -39.5 · 95% CI -264.32 to 185.32
  • EDP-305 1 mg vs Placebo · ANCOVA · p = 0.974 · Least squares mean difference: 2.93 · 95% CI -229.6 to 235.46
  • EDP-305 2.5 mg vs Placebo · ANCOVA · p = 0.793 · Least squares mean difference: -26.05 · 95% CI -283.24 to 231.15

Adverse events

Collected over Up to 16 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
EDP-305 1 mg0/31 (0%)1/31 (3.2%)23/31 (74.2%)
EDP-305 2.5 mg0/28 (0%)2/28 (7.1%)24/28 (85.7%)
Placebo0/9 (0%)0/9 (0%)8/9 (88.9%)
Most frequent serious events
Most frequent serious events
EventEDP-305 1 mgEDP-305 2.5 mgPlacebo
HeadacheNervous system disorders0/311/280/9
FatigueGeneral disorders0/311/280/9
Abdominal painGastrointestinal disorders0/311/280/9
PruritisGastrointestinal disorders0/311/280/9
UrticariaGastrointestinal disorders0/311/280/9
Escherichia urinary tract infectionInfections and infestations0/311/280/9
Bacterial infectionInfections and infestations1/310/280/9
Most frequent other events
Showing 10 of 40
Most frequent other events
EventEDP-305 1 mgEDP-305 2.5 mgPlacebo
PruritusSkin and subcutaneous tissue disorders11/3116/283/9
HeadacheNervous system disorders3/315/283/9
Pruritus generalisedSkin and subcutaneous tissue disorders5/319/280/9
Dry mouthGastrointestinal disorders0/311/282/9
Back painMusculoskeletal and connective tissue disorders0/311/282/9
Abdominal pain upperGastrointestinal disorders4/311/280/9
ContusionInjury, poisoning and procedural complications0/310/281/9
CoughRespiratory, thoracic and mediastinal disorders0/311/281/9
EpistaxisRespiratory, thoracic and mediastinal disorders0/310/281/9
Sinus congestionRespiratory, thoracic and mediastinal disorders0/310/281/9

Baseline characteristics

Age, Continuous
Age, Continuous(years)EDP-305 1 mgEDP-305 2.5 mgPlaceboTotal
Mean57.4 ± 8.6154.9 ± 10.9256.9 ± 8.4956.3 ± 9.55
Sex: Female, Male
Sex: Female, Male(Participants)EDP-305 1 mgEDP-305 2.5 mgPlaceboTotal
Female3127967
Male0101
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)EDP-305 1 mgEDP-305 2.5 mgPlaceboTotal
Hispanic or Latino3205
Not Hispanic or Latino2725961
Unknown or Not Reported1102
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)EDP-305 1 mgEDP-305 2.5 mgPlaceboTotal
White2827964
All other races3104
Region of Enrollment
Region of Enrollment(participants)EDP-305 1 mgEDP-305 2.5 mgPlaceboTotal
United States1612230
Canada1113
Australia2125
Spain3227
United Kingdom66113
Austria0202
Belgium0101
France0101
Germany2114
Netherlands1102
08

Study locations

86 sites
  • Digestive Health Specialists of the Southeast
    Dothan, Alabama 36305, United States
  • Arkansas Diagnostic Center
    Little Rock, Arkansas 72205, United States
  • Texas Clinical Research Institute
    Little Rock, Arkansas 76012, United States
  • Southern California Research Center
    Coronado, California 92118, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • California Liver Research Institue
    Pasadena, California 91105, United States
  • Pasadena Liver Center
    Pasadena, California 91105, United States
  • Inland Empire Liver Foundation
    Rialto, California 92377, United States
  • California Pacific Medical Center
    San Francisco, California 94115, United States
  • South Denver Gastroenterology - Swedish Medical Center Office
    Englewood, Colorado 80113, United States
  • Yale School of Medicine
    New Haven, Connecticut 06520, United States
  • Gastroenterology Consultants of Clearwater
    Clearwater, Florida 33756-3839, United States
  • Nature Coast Clinical Research
    Inverness, Florida 34452, United States
  • University of Miami Leonard M. Miller School of Medicine
    Miami, Florida 33136, United States
  • Consultative Gastroenterology
    Atlanta, Georgia 30312, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • Louisiana Research Center
    Shreveport, Louisiana 71105, United States
  • Mercy Medical Center-McAuley Plaza
    Baltimore, Maryland 21202, United States
  • Johns Hopkins University
    Baltimore, Maryland 21287, United States
  • Digestive Disease Associates
    Catonsville, Maryland 21228, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Henry Ford Hospital
    Detroit, Michigan 48377, United States
  • CHI Health
    Omaha, Nebraska 68124, United States
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Montefiore Medical Center - Bronx
    Bronx, New York 10461-1925, United States
  • Northwell Health
    Manhasset, New York 11030, United States
  • Concorde Medical Group
    New York, New York 10016, United States
  • Mount Sinai Beth Isreal
    New York, New York 10016, United States
  • Weill Cornell Medical College
    New York, New York 10024, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • University of Pittsburgh Medical Center - Center for Liver Disease
    Pittsburgh, Pennsylvania 15213, United States
  • The Liver Institute at Methodist Dallas Medical Center
    Dallas, Texas 75203, United States
  • Liver Consultants of Texas
    Dallas, Texas 76104, United States
  • Baylor Saint Luke's Medical Center
    Houston, Texas 77030, United States
  • American Research Corporation at the Texas Liver Institute
    San Antonio, Texas 78215, United States
  • Liver Institute of Virginia-Bremo
    Richmond, Virginia 23602, United States
  • Swedish First Hill Campus
    Seattle, Washington 98104, United States
  • University of Washington
    Seattle, Washington 98195-6460, United States
  • Nepean Hospital
    Kingswood, New South Wales 2747, Australia
  • Monash Medical Centre
    Clayton, Victoria 3168, Australia
  • Linear Clinical Research
    Perth, Western Australia 6000, Australia
  • Klinikum Klagenfurt Am Wörthersee
    Klagenfurt am Wörthersee, Carinthia 9020, Austria
  • Medizinische Universität Innsbruck
    Innsbruck, Tyrol 6020, Austria
  • Klinikum Wels-Grieskirchen
    Wels, Upper Austria 4600, Austria
  • CHU de Liège, Cardiology Dept.
    Liège, Liege 4000, Belgium
  • Ziekenhuis Oost-Limburg
    Genk, Limburg 3600, Belgium
  • Universitair Ziekenhuis Gent
    Gent, Oost-vlaanderen 9000, Belgium
  • London Health Sciences Centre University Hospital
    London, Ontario N6A 5A5, Canada
  • Toronto General Hospital
    Toronto, Ontario M5G 2C4, Canada
  • Toronto Liver Center
    Toronto, Ontario M6H 3M1, Canada
  • Nouvel Hôpital Civil
    Strasbourg cedex, Alsace 67091, France
  • Hôpital Haut-Lévêque
    Pessac, Aquitaine 33600, France
  • Hôpital Saint-Antoine
    Paris Cedex 12, Ile-de-france 75012, France
  • Hôpital Paul Brousse
    Villejuif Cedex, Ile-de-france 94800, France
  • Hôpital Saint-Eloi
    Montpellier cedex 5, Languedoc-roussillon 34295, France
  • Centre Hospitalier Régional Universitaire de Lille
    Lille, NORD Pas-de-calais 59037, France
  • Centre Hospitalier Universitaire Amines-Picardie Hôpital Sud
    Amiens Cedex 1, Picardie 80054, France
  • Hôpital de la Croix Rousse
    Lyon Cedex 04, Rhone-alpes 69317, France
  • Universitätsklinikum Würzburg
    Würzburg, Bayern 97080, Germany
  • Universitätsklinikum Frankfurt
    Frankfurt am Main, Hessen 60590, Germany
  • Universitätsklinikum Bonn
    Bonn, Nordrhein-westfalen 53127, Germany
  • Universitaetsklinikum Essen
    Essen, Nordrhein-westfalen 45122, Germany
  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz
    Mainz, Rheinland-pfalz 55131, Germany
  • Universitätsklinikum Leipzig
    Leipzig, Sachsen 04103, Germany
  • Charité Universitätsmedizin Berlin
    Berlin, 13353, Germany
  • Vrije Universiteit Medisch Centrum
    Amsterdam, Noord-holland 1081 HV, Netherlands
  • Leiden Universitair Medisch Centrum
    Leiden, Zuid-holland 2333 ZA, Netherlands
  • Universitair Medisch Centrum Utrecht
    Utrecht, 3584 CX, Netherlands
  • Hospital Universitario Donostia
    San Sebastian, Guipuzcoa 20014, Spain
  • Hospital Universitario Virgen de la Arrixaca
    El Palmar, Murcia 30120, Spain
  • Hospital Universitari Vall d'Hebrón
    Barcelona, 08029, Spain
  • Hospital Universitario Ramón Y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario Marqués de Valdecilla
    Santander, 39008, Spain
  • Hospital Universitario Virgen del Rocio
    Sevilla, 41013, Spain
  • Hospital Universitari i Politecnic La Fe de Valencia
    Valencia, 46026, Spain
  • Universidad de Valladolid - Hospital Universitario Rio Hortega
    Valladolid, 47010, Spain
  • University Hospitals Birmingham NHS Foundation Trust
    Birmingham, England B15 2TT, United Kingdom
  • Cambridge University Hospitals NHS Foundation Trust
    Cambridge, England CB2 0QQ, United Kingdom
  • The Leeds Teaching Hospitals NHS Trust
    Leeds, England LS9 7TF, United Kingdom
  • King's College Hospital NHS Foundation Trust
    London, England SE5 9RS, United Kingdom
  • Norfolk and Norwich University Hospitals NHS Foundation Trust
    Norwich, England NR4 7UY, United Kingdom
  • Queen's Medical Centre - Nottingham
    Nottingham, England NG7 2UH, United Kingdom
  • Portsmouth Hospitals NHS Trust
    Portsmouth, England PO6 3LY, United Kingdom
  • NHS Lothian
    Edinburgh, Scotland EH16 4SA, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Dec 2019, 23 months.

Results were first posted in May 2021, 1 year 4 months after primary completion. A results delay was requested in Dec 2020.

Of 21 phase 2 interventional studies under Liver Cirrhosis, Biliary, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 34. This study's 23 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2017
First posted
Jan 9, 2018
StartActual
Dec 27, 2017
Primary completionActual
Dec 19, 2019
CompletionActual
Jan 16, 2020
Results delay requested
Dec 8, 2020
Results first posted
May 18, 2021
Last update
May 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03394924
Collaborators
Pharmaceutical Research Associates, Triangle Biostatistics, LLC
Responsible party
Sponsor
First posted
Jan 9, 2018
Start date
Dec 27, 2017
Primary completion
Dec 19, 2019
Completion
Jan 16, 2020
Results posted
May 18, 2021
Last update
May 18, 2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: EDP-305

Start the discussion